Search Results - "Schejbalová, Stanislava"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
  2. 2
  3. 3

    AT1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats by Vaněčková, Ivana, Kopkan, Libor, Husková, Zuzana, Vaňourková, Zdenka, Schejbalová, Stanislava, Červenka, Luděk, Kramer, Herbert J

    Published in Vascular pharmacology (01-07-2007)
    “…Abstract The effectiveness of antisense (AS) phosphorothioated oligodeoxynucleotides (AS-ODN) targeted to the angiotensin (ANG) type 1 (AT1 ) receptor, was…”
    Get full text
    Journal Article
  4. 4

    Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats by Vaněčková, Ivana, Kramer, Herbert J., Bäcker, Angela, Schejbalová, Stanislava, Vernerová, Zdena, Eis, Václav, Opočenský, Martin, Dvořák, Pavel, Červenka, Luděk

    Published in Vascular pharmacology (01-09-2006)
    “…Male heterozygous Ren-2 transgenic rats and Hannover Sprague–Dawley rats fed a normal or high-salt diet were either untreated or treated with the nonselective…”
    Get full text
    Journal Article
  5. 5

    Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade by Vanecková, Ivana, Kopkan, Libor, Husková, Zuzana, Vanourková, Zdenka, Schejbalová, Stanislava, Cervenka, Ludek, Kramer, Herbert J

    Published in Kidney & blood pressure research (2007)
    “…The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of…”
    Get more information
    Journal Article
  6. 6

    AT 1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats by Vaněčková, Ivana, Kopkan, Libor, Husková, Zuzana, Vaňourková, Zdenka, Schejbalová, Stanislava, Červenka, Luděk, Kramer, Herbert J.

    Published in Vascular pharmacology (2007)
    “…The effectiveness of antisense (AS) phosphorothioated oligodeoxynucleotides (AS-ODN) targeted to the angiotensin (ANG) type 1 (AT 1) receptor, was studies in…”
    Get full text
    Journal Article